BioScrip (NASDAQ:BIOS) will issue its quarterly earnings data before the market opens on Tuesday, November 6th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. BioScrip has set its FY18 guidance at ($0.40-0.34) EPS.Parties that are interested in registering for the company’s conference call can do so using this link.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Tuesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.04). The company had revenue of $175.79 million during the quarter, compared to the consensus estimate of $169.00 million. On average, analysts expect BioScrip to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ:BIOS opened at $2.82 on Monday. The company has a market cap of $361.09 million, a P/E ratio of -6.41 and a beta of 0.42. BioScrip has a 12-month low of $1.83 and a 12-month high of $3.26.
BIOS has been the topic of several analyst reports. BidaskClub raised BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. Barrington Research reaffirmed a “buy” rating and set a $4.00 target price on shares of BioScrip in a research report on Friday, October 5th. Finally, Zacks Investment Research cut BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $3.56.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
See Also: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.